Acknowledging Patient Heterogeneity in Economic Evaluation
暂无分享,去创建一个
James E. Stahl | Johan L. Severens | Mark Sculpher | Dirk De Ruysscher | Manuela A. Joore | Andrew H. Briggs | M. Sculpher | A. Briggs | D. Ruysscher | J. Stahl | J. Severens | M. Joore | B. Ramaekers | M. Candel | J. Grutters | A. Boer | Janneke P. C. Grutters | Math J. Candel | Albert Boer | Bram L. T. Ramaekers
[1] Anirban Basu,et al. Value of Information on Preference Heterogeneity and Individualized Care , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.
[2] Martin J Buxton,et al. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria. , 2003, Health economics.
[3] Anirban Basu,et al. A CTSA Agenda to Advance Methods for Comparative Effectiveness Research , 2011, Clinical and translational science.
[4] Joanna Coast,et al. Using discrete choice experiments to understand preferences for quality of life. Variance-scale heterogeneity matters. , 2010, Social science & medicine.
[5] R. Bast,et al. Individualized care for patients with cancer - a work in progress. , 2004, The New England journal of medicine.
[6] Gordon H Guyatt,et al. Subgroup Analysis of Trials Is Rarely Easy (SATIRE): a study protocol for a systematic review to characterize the analysis, reporting, and claim of subgroup effects in randomized trials , 2009, Trials.
[7] Mark Sculpher,et al. Subgroups and Heterogeneity in Cost-Effectiveness Analysis , 2012, PharmacoEconomics.
[8] M. Mcgrath. Cost Effectiveness in Health and Medicine. , 1998 .
[9] S. Pocock,et al. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems , 2002, Statistics in medicine.
[10] M. Bala,et al. Pharmacogenomics and the Evolution of Healthcare , 2012, PharmacoEconomics.
[11] A. L. Caze. Does pharmacogenomics provide an ethical challenge to the utilisation of cost-effectiveness analysis by public health systems? , 2012, PharmacoEconomics.
[12] P. Dolan,et al. Discrete choice experiments in health economics. For better or for worse? , 2004, The European journal of health economics : HEPAC : health economics in prevention and care.
[13] G H Guyatt,et al. A Consumer's Guide to Subgroup Analyses , 1992, Annals of Internal Medicine.
[14] Nick Freemantle,et al. Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? , 2001, BMJ : British Medical Journal.
[15] David J Spiegelhalter,et al. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost‐effectiveness modelling , 2003, Statistics in medicine.
[16] T. Peters,et al. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. , 2001, Health technology assessment.
[17] Verena Tiefenbeck,et al. For better or for worse? Empirical evidence of moral licensing in a behavioral energy conservation campaign , 2013 .
[18] S. Chick,et al. A taxonomy of model structures for economic evaluation of health technologies. , 2006, Health economics.
[19] Grazyna Adamiak,et al. Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .
[20] D. Marshall,et al. Design and Analysis Issues for Economic Analysis Alongside Clinical Trials , 2009, Medical care.
[21] F. Pang,et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. , 2004, Health technology assessment.
[22] M. Sculpher,et al. Recognising diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. Authors' reply , 2002 .
[23] C. Dewa,et al. Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health Interventions , 2012, PharmacoEconomics.
[24] J. Singh. International society for pharmacoeconomics and outcomes research , 2006 .
[25] Daniel Polsky,et al. Economic Evaluation in Clinical Trials , 2007 .
[26] Andrew R Willan,et al. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. , 2004, Health economics.
[27] P. Dolan,et al. Discrete choice experiments in health economics , 2004, The European Journal of Health Economics, formerly: HEPAC.
[28] Janneke Grutters,et al. The role of the expected value of individualized care in cost-effectiveness analyses and decision making. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[29] A. Chant,et al. Can overall results of clinical trials be applied to all patients? , 1995, Lancet.
[30] P. Rothwell. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation , 2005, The Lancet.
[31] Charles Normand,et al. Optimisation versus certainty: understanding the issue of heterogeneity in economic evaluation. , 2004, Social science & medicine.
[32] M. Sculpher,et al. Decision Modelling for Health Economic Evaluation , 2006 .
[33] M. Sculpher. Reflecting heterogeneity in patient benefits: the role of subgroup analysis with comparative effectiveness. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[34] M. Sculpher,et al. Recognizing diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. , 2001, Health economics.
[35] A. Briggs,et al. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. , 2002, Health economics.
[36] S. Assmann,et al. Subgroup analysis and other (mis)uses of baseline data in clinical trials , 2000, The Lancet.
[37] Andrew Briggs,et al. Access with Evidence Development in the UK , 2012, PharmacoEconomics.
[38] Modelling approaches: the case of schizophrenia. , 2008, PharmacoEconomics.
[39] J Dowie. Towards the equitably efficient and transparently decidable use of public funds in the deep blue millennium. , 1998, Health economics.
[40] Andrew Briggs,et al. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20 536 individuals , 2005, The Lancet.
[41] On pharmacogenomics and cost-effectiveness analysis at the individual level , 2012, PharmacoEconomics.
[42] S. Dixon,et al. The Role of Patient Preferences in Cost-Effectiveness Analysis , 2012, PharmacoEconomics.
[43] M. Relling,et al. Moving towards individualized medicine with pharmacogenomics , 2004, Nature.
[44] Andrew Briggs,et al. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study , 2006, Heart.
[45] Simon G Thompson,et al. Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations. , 2005, Health economics.
[46] Gregory S Zaric,et al. The Impact of Ignoring Population Heterogeneity when Markov Models are Used in Cost-Effectiveness Analysis , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.
[47] M. Sculpher,et al. Shared treatment decision making in a collectively funded health care system: possible conflicts and some potential solutions. , 2002, Social science & medicine.
[48] M. Drummond,et al. What do international pharmacoeconomic guidelines say about economic data transferability? , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[49] S. Wilson. Methods for the economic evaluation of health care programmes , 1987 .
[50] David Parkin,et al. Recognising diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. A response to Sculpher and Gafni. , 2002, Health economics.